MedTrace Logo

Assessing Use Of Mifepristone After Progestin Priming For Use As "Missed Period Pills"

NCT04676776 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2021-08-12

No results posted yet for this study

Summary

This study will assess the effectiveness and acceptability of a 3-day missed period pill regimen.

Conditions

  • Missed Menstrual Period

Interventions

DRUG

Levonorgestrel

All participants receive 1.5 mg levonorgestrel on day 1

DRUG

Mifepristone

All participants receive 200 mg mifepristone on day 3

Sponsors & Collaborators

  • Cuidado Integral de la Mujer, Gineclinic, S.C.

    collaborator UNKNOWN

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Beverly H Winikoff, MD · Gynuity Health Projects

  • Holly A Anger · Gynuity Health Projects

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-25
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676776 on ClinicalTrials.gov